Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash & Equivalents (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cash & Equivalents for 4 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 87.64% year-over-year to $5.7 million, compared with a TTM value of $5.7 million through Sep 2025, down 87.64%, and an annual FY2024 reading of $25.0 million, down 3.14% over the prior year.
  • Cash & Equivalents was $5.7 million for Q3 2025 at Atara Biotherapeutics, down from $16.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $101.7 million in Q1 2022 and bottomed at $5.7 million in Q3 2025.
  • Average Cash & Equivalents over 4 years is $46.0 million, with a median of $45.9 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents decreased 0.5% in 2023, then crashed 87.64% in 2025.
  • Year by year, Cash & Equivalents stood at $92.9 million in 2022, then crashed by 72.2% to $25.8 million in 2023, then fell by 3.14% to $25.0 million in 2024, then crashed by 77.06% to $5.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ATRA at $5.7 million in Q3 2025, $16.9 million in Q2 2025, and $13.8 million in Q1 2025.